64 results about "HPV infection" patented technology

The invention provides a biomarker for cervical lesion caused by low folic acid mediated HPV infection and application of the biomarker, the biomarker is IGF2BP3 and miR-27a, and the IGF2BP3 and the miR-27a can be used as a therapeutic target and a research tool for cervical lesion caused by low folic acid mediated HPV infection. The small nucleic acid targeting IGF2BP3 and miR-27a is delivered through the folic acid modified exosome in cervical lesion treatment, and the delivery efficiency and the treatment effect are remarkably improved.

The invention refers to the use of PAP-I, a plant ribosome inactivating protein (RIP), or a functional variant thereof for treatment of human papillomavirus (HPV) infection and preventing or treating diseases or conditions associated with HPV infection.

The present application relates to a kind of traditional Chinese medicine for treating female HPV infection, which is prepared from the following weight ratio of traditional Chinese medicine raw materials: 2-4 parts of catechu, 2-4 parts of half lotus, 2-4 parts of snakeberry, 1-2 parts of longjin, 1-2 parts of gotu kola, 1-2 parts of wintergreen, 1-2 parts of coptis, and 1-2 parts of sophora. The present application can effectively treat female HPV infection.

The invention belongs to the field of biological medicine, and relates to a traditional Chinese medicine composition for treating high-risk HPV infection. The traditional Chinese medicine composition is prepared from the following traditional Chinese medicine raw materials: radix sophorae flavescentis, rhizoma smilacis glabrae, fructus cnidii, cyrtomium fortunei, dried alum, pericarpium zanthoxyli, cortex phellodendri and raw radix stemonae.

Aspects herein include methods, kits, and systems for evaluating a subject comprising detecting genetic mutation(s) in the DNA sequence of one or more oral cavity squamous cell carcinoma (OCSCC) biomarker(s) in a biological sample from the subject comprising DNA, wherein the OCSCC biomarker(s) comprise TP53, CDKN2A, FAT1, CASP8, NOTCH1, PIK3CA, and / or HRAS along with detecting or determining an HPV infection.

The invention discloses application of berberine or berberine hydrochloride in preparation of drugs for resisting HPV infection related diseases. Preferably, the berberine is an extract of natural plants such as coptis chinensis, golden cypress, berberis poiretii schneid or Chinese mahonia. According to the application, the new application of the berberine or the hydrochloride thereof in the aspect of resisting the HPV virus is expanded, and the berberine or the hydrochloride thereof is used for preparing the preparation for resisting the HPV infection, so that diseases related to the HPV infection can be prevented or treated, and the virus is promoted to become negative. As a natural plant extract, berberine is high in safety and not easy to generate drug resistance, and has important clinical significance when being used for preparing Chinese patent medicine products for resisting HPV infection.

This invention discloses a traditional Chinese medicine composition for treating HPV infection, its preparation, and its uses. The composition comprises the following ingredients in the indicated weight percentages: 10-40 parts of *Hedyotis diffusa*, 10-30 parts of *Smilax glabra*, 10-30 parts of *Hedyotis diffusa*, 10-30 parts of *Paeonia suffruticosa*, 10-40 parts of *Lithospermum erythrorhizon*, 10-30 parts of *Dictamnus dasycarpus*, 10-30 parts of *Radix Paeoniae Rubra*, 10-30 parts of *Cicadae Periostracum*, 10-30 parts of *Astragalus membranaceus*, and 10-30 parts of *Glycyrrhiza uralensis*. It effectively inhibits the replication of human papillomavirus (HPV) nucleic acid, thereby effectively treating cervical HPV infection caused by HPV, as well as infectious skin diseases such as cervical precancerous lesions and condyloma acuminata caused by HPV infection.

The invention discloses a nano vaccine for treating HPV (human papilloma virus) infection related cervical lesions as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. In order to solve the problem that the response rate of an existing cervical lesion treatment vaccine does not meet clinical requirements, the hybrid membrane with enhanced immunogenicity and improved safety is prepared by applying a membrane fusion technology and combining an autologous tumor cell membrane and an escherichia coli cytoplasmic membrane; meanwhile, PLGA nano particles loaded with HPV16 E5 / E6 / E7 specific CTL epitope long peptide are used as a delivery carrier, and the HM-NPs-LP nano vaccine co-delivering the hybrid membrane and the HPV16 specific antigen peptide is developed. According to the nano vaccine, tumor cells and HPV16 E5 / E6 / E7 specific CTL epitope long peptide are taken as antigens for immunotherapy, dual immune activation of broad spectrum and specific antigens can be realized, personalized multi-effect treatment capacity for HPV infection related cervical diseases is exerted, targeted killing of HPV infection and pathological cells is enhanced, pathological relapse is prevented, and the nano vaccine has good clinical application prospects. And a new strategy is provided for individualized precise immunotherapy.

The application discloses a gel preparation preparation method for improving cervical HPV infection and establishing a preventive barrier, relates to the technical field of gel preparation, and aims to solve the technical problems that the existing treatment methods are mostly focused on treating infected patients, and there are obvious deficiencies in the prevention of HPV infection, especially in establishing an effective preventive barrier in uninfected people, including: a crushing mechanism, which is mainly used for crushing raw materials, the crushing mechanism comprises a cabinet body, a cabinet door is arranged on one side of the cabinet body, a crushing barrel is arranged in the cabinet door, and a rotating motor matched with the crushing barrel is arranged on the cabinet door; a reverse osmosis mechanism, which is mainly used for controlling the osmotic pressure of the gel. The application has the advantages of activating local immune cells of the cervix, promoting cytokine secretion, enhancing the immune clearance ability of the body to HPV virus, providing long-acting preventive protection for the cervix, and reducing the risk of HPV infection.

The invention discloses a medicine slow-release device for cervical HPV infection, which comprises a cylinder, the top of the cylinder is hermetically connected with an end, the end is provided with medicine outlets at equal angles, and the middle of the bottom surface of the cylinder is connected with a piston rod in a penetrating manner; a protective cover is hinged to the top of the barrel at equal angles, the protective cover covers the outer side of the end, a regulation and control mechanism is arranged on the inner side of the bottom of the barrel, the regulation and control mechanism drives the protective cover to rotate in an opening and closing mode in a meshing rotation mode, and meanwhile the protective cover is used for protecting the end; an installation locking mechanism is arranged on the cylinder body, and the installation locking mechanism is used for firmly connecting the end heads in a rotating connection mode. According to the medicine slow release device for cervical HPV infection, the cleanliness of the medicine delivery end can be kept, the medicine delivery end does not make contact with the external environment, the end can be conveniently and firmly connected and rapidly disassembled and assembled, then disinfection treatment is convenient, meanwhile, the medicine delivery speed can be controlled, and medicine delivery is uniform.

The invention provides a therapeutic target for high-risk human papilloma virus infection diseases and application of the therapeutic target. The important pathogenic factor EC-HPV16 / 18-Fs of the human papilloma virus infection disease is determined, and the pathogenic factor EC-HPV16 / 18-Fs can be used as a target to prepare a targeted regulation reagent for treating the human papilloma virus infection disease; or, a reagent for targeted regulation is screened by taking the target as a target. The invention also provides nucleic acid inhibitors for targeted modulation. The invention provides a new target for clinical treatment and detection of human papilloma virus infection diseases.

Safe, rapid, and efficient methods for producing antigen-specific T cells recognizing human papilloma virus (HPV antigens); HPV-specific T cells, and methods for treating HPV infections and HPV-related malignancies by adoptive transfer of HPV-specific T cells.

This invention discloses a composition and its preparation method for treating human papillomavirus (HPV) and cervical intraepithelial neoplasia (CIN), belonging to the field of traditional Chinese medicine technology. The formula consists of 6-15 parts of American cockroach, 5-11 parts of hawthorn, 5-11 parts of chicory, 3-9 parts of *Scutellaria baicalensis*, 8-20 parts of *Sophora flavescens*, and 6-15 parts of *Cnidium monnieri*, and also contains 0.01-1 parts by weight of toad venom. The dosage form is one or more of the following: external gel, rinse, foam, suppository, and film preparation. It has high safety and is suitable for HPV infection and CIN changes, solving the problem of poor efficacy in existing treatments.

This invention discloses a dual-targeting DNA vaccine delivery system based on calcium phosphate lipid nanoparticles, belonging to the field of biomedicine. The delivery system comprises calcium phosphate containing histone H1 and an HPV E6 / E7 fusion gene plasmid, and a lipid bilayer membrane of DSPE-PEG-2000-Mannose. This system achieves targeted uptake by dendritic cells through mannose modification and relies on histone H1-mediated DNA nuclear transport. The dual targeting significantly enhances antigen expression efficiency. In vitro and in vivo experiments have demonstrated that this delivery system exhibits good biocompatibility and high stability, effectively activating antigen-specific T-cell immune responses, and possesses both HPV infection prevention and cervical cancer treatment effects, providing a new strategy for cervical cancer prevention and treatment.

The application discloses a recombinant humanized collagen composition for resisting HPV infection and a preparation method thereof. The composition comprises the following components in percentage by mass: 30-45% of a recombinant humanized collagen fusion protein, 30-40% of probiotics and 20-35% of glycogen. The recombinant humanized collagen fusion protein comprises, from N-terminal to C-terminal, a recombinant humanized collagen fragment and a human fibronectin fragment connected in sequence. The recombinant humanized collagen fragment and the human fibronectin fragment are connected by a linker. The recombinant humanized collagen fusion protein in the composition can promote the adhesion and colonization of the probiotic composition to the vaginal epithelial cells, rapidly improve the microbial environment of the vagina and effectively enhance the resistance of the vagina to harmful bacteria and viruses.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to an external traditional Chinese medicine composition for resisting HPV infection as well as a preparation method, a component analysis method and application thereof. The external traditional Chinese medicine composition is prepared from the following raw materials: rhizoma atractylodis, cortex phellodendri, radix sophorae flavescentis, rhizoma coptidis, rhizoma polygoni cuspidati, herba taraxaci, humifuse euphorbia herb, herba selaginellae, semen juglandis and fructus cnidii, all the medicines are used together, both symptoms and root causes are taken into consideration, middle-jiao can be healthy to prevent endogenesis of damp evil, lower-jiao can be cleared to remove damp-heat and excess syndromes, and the external traditional Chinese medicine composition has the effects of detoxifying and resisting viruses and conforms to the pathogenesis characteristics of HPV infection. The external traditional Chinese medicine composition can directly act on a lesion part through a mucous membrane drug delivery system by being directly applied to an affected part, the treatment effect is remarkable, and gastrointestinal discomfort caused by oral medicine can be reduced.

Disclosed herein includes a nanoplasmonic sensor for molecular characterization of human papillomavirus (HPV), and diseases and disorders associated with HPV infection. In some embodiments. the nanoplasmonic sensor can also be used at the point-of-care. The nanoplasmonic sensor utilizes an optical phenomenon that occurs between a metal nanoparticle and a dielectric—localized surface plasmon resonance (LSPR)—for the detection of viral nucleic acids. In some embodiments. the spectral peak shift is a function of target sequence concentration.

The invention discloses an ergothioneine and achyranthes bidentata polysaccharide composition for inhibiting HPV and a preparation method of the ergothioneine and achyranthes bidentata polysaccharide composition, and relates to the technical field of biological medicines. The composition is prepared from the following components in parts by mass: 1 to 5 parts of ergothioneine, 3 to 10 parts of achyranthes bidentata polysaccharide, 0.2 to 1.2 parts of a CXCR4 antagonist, 0.5 to 2 parts of sodium hyaluronate, 10 to 20 parts of a polyhydric alcohol cosolvent and 60 to 80 parts of deionized water, wherein the CXCR4 antagonist has a specific structure as shown in formula 1. According to the composition, through targeted intervention of the CXCR4 antagonist, delivery network construction of achyranthes bidentata polysaccharides and stable synergy of ergothioneine, a multi-mechanism synergistic effect is achieved, and the inhibition effect on HPV infection and the preparation stability are improved.

The application discloses a traditional Chinese medicine composition and a traditional Chinese medicine preparation for treating HPV infection. Specifically, the traditional Chinese medicine composition comprises the following components: radix codonopsis 15-45 parts, rhizoma atractylodis macrocephalae 7-25 parts, radix astragali 20-60 parts, radix pseudostellariae 7-25 parts, radix ophiopogonis 7-25 parts, radix rehmanniae 10-30 parts, coriolus 15-45 parts, ganoderma 15-45 parts, smilax riparia 20-60 parts, oldenlandia 15-35 parts, herba taraxaci 15-35 parts, morus 20-40 parts, coix 15-35 parts, gardenia 7-25 parts, salvia miltiorrhiza 10-30 parts, portulaca 15-45 parts, poria 10-30 parts, isatis root 10-30 parts, dendrobium 7-25 parts, schisandra 7-25 parts, licorice 10-20 parts, and cyperus 15-35 parts.

This invention belongs to the field of biological detection technology, and particularly relates to a reproductive tract HPV-mRNA-E6 / E7 detection system and method based on nanopore sequencing. The system includes a sample pretreatment module, an RNA extraction and purification module, a reverse transcription module, a nanopore sequencing module, and a bioinformatics analysis module. The method includes the following steps: (1) reproductive tract sample collection and pretreatment; (2) extraction and purification of HPV-mRNA in the sample; (3) reverse transcription of the purified HPV-mRNA into cDNA; (4) nanopore sequencing of the cDNA to obtain raw sequencing data; (5) filtering, comparing, and annotating the sequencing data through the bioinformatics analysis module to achieve HPV type identification and quantitative analysis of E6 / E7 gene expression levels. This invention utilizes the advantages of nanopore sequencing, such as long read length and real-time detection, combined with the specificity of E6 / E7 mRNA as a biomarker of active infection. It can directly detect latent and active HPV infection, improve detection sensitivity, accurately distinguish infection types, and shorten the detection cycle. It enables rapid, accurate, and high-throughput detection of active HPV infection in the genital tract, providing reliable technical support for early screening, disease monitoring, and prognostic assessment of HPV-related diseases such as cervical cancer.

The invention provides a skin organoid HPV infection model based on a human embryonic stem cell source and a construction method and application thereof, and relates to the technical field of molecular biology, the construction method comprises the following steps: integrating an HPV genome to an AAVS1 site of genome DNA of a human embryonic stem cell to obtain the human embryonic stem cell carrying the HPV genome, and performing induced differentiation and activation of the HPV genome to obtain the human embryonic stem cell carrying the HPV genome. A skin-like organ HPV infection model is formed, stable heredity and controllable expression of an HPV genome are achieved, virus particle assembly is achieved through induced differentiation, establishment of a virus replication environment, activation of HPV early gene expression, driving of HPV genome replication and induction of late gene expression, and the natural infection state of HPV is simulated. The technical problem that in the prior art, an infection model cannot simulate the life cycle of HPV dependent terminal differentiation is solved, and an irreplaceable technical platform is provided for research of an HPV pathogenic mechanism and research and development of antiviral drugs and vaccines.

The application relates to application of a dihydropyridine compound or a salt thereof in preparation of a medicine for preventing and / or treating HPV infection, and belongs to the technical field of medicines and pharmaceutical preparations. The application provides application of the dihydropyridine compound or the salt thereof in preparation of the medicine for preventing and / or treating HPV infection, wherein the dihydropyridine compound is selected from one or more of nifedipine, amlodipine, lercanidipine, nimodipine, nitrendipine, nisoldipine, felodipine, benidipine, lacidipine and azelnidipine. The application scheme first reports the application of the dihydropyridine compound or the salt thereof in prevention and / or treatment of HPV, and in-vitro cell experiments are carried out through azelnidipine in the dihydropyridine compound, and further, the inhibiting effect of the dihydropyridine compound on HPV virus is verified through medicine administration of a mouse intradermal virus inoculation model and medicine administration of a mouse vaginal virus inoculation model.

This invention relates to antisense oligonucleotides targeting different subtypes of human papillomavirus (HPV) oncogenes and their applications. The ASO molecules are 14–40 bases in length and specifically pair with specific regions of target genes. This invention also relates to the following applications of the ASO molecules: (1) preparing preparations to inhibit HPV virus expression; or (2) preparing drugs or drug compositions for treating diseases related to HPV infection; or (3) treating diseases related to HPV infection; or (4) inhibiting the expression of HPV virus genes.

Aspects herein include methods, kits, and systems for evaluating a subject comprising detecting genetic mutation(s) in the DNA sequence of one or more oral cavity squamous cell carcinoma (OCSCC) biomarker(s) in a biological sample from the subject comprising DNA, wherein the OCSCC biomarker(s) comprise TP53, CDKN2A, FAT1, CASP8, NOTCH1, PIK3CA, and / or HRAS along with detecting or determining an HPV infection.

The invention belongs to the technical field of medical animal model construction, and particularly relates to a construction method of an animal model for simulating various stages from HPV (human papillomavirus) continuous infection to cervical canceration in a natural infection state and application of the animal model. According to the method, a drug immunosuppressor for promoting HPV infection is combined with MmuPV1 for mouse lower genital tract infection modeling; the constructed animal model is stable and uniform in papilloma virus infection, high in modeling rate, low in fatality rate, short in modeling time, controllable in process and good in reproducibility, can completely reproduce the whole process from HPV continuous infection to cervical canceration, accords with clinical practice, improves the efficiency and quality of model construction, and is suitable for popularization and application. An ideal animal model is provided for follow-up research on an HPV infection carcinogenic mechanism and a virus host interaction mechanism, meanwhile, the model can assist in research, development and screening of clinical treatment methods for preventing and treating cervical lesions at all stages, and clinical transformation, new drug research and development and other work are promoted.

The application belongs to the technical field of biological medicine, and provides a recombinant type III human collagen peptide for resisting HPV infection and a preparation method and application thereof, an amino acid sequence of which is a coding sequence of positions 991-1032 of type III human collagen UniProtKB: P02461 repeated three times, named as ATHPV3, and an amino acid sequence of which is shown as SEQ ID NO. 1. After expression and purification, the recombinant type III human collagen peptide with a molecular weight of about 13 kD is obtained, can be specifically combined with HPV 16 / 18 L1 protein, has multiple hydrogen bond actions, and can inhibit pseudo-virus infection of 293T cells at high and medium concentrations. The application successfully obtains a recombinant type III human collagen peptide with good purity, which can be combined with HPV 16 / 18 L1 and can effectively inhibit HPV 16 / 18 pseudo-virus infection of 293T cells, and provides an effective candidate drug for preventing and treating HPV infection.

A method of treating or preventing an HPV infection or a disease or condition associated with an HPV infection comprises exposing a subject with an HPV infection to microwave energy, where the microwave energy degrades the HPV E6 protein.

The invention relates to a capsule for treating gynecological diseases and a preparation method thereof. The capsule is prepared from polygonum cuspidatum, sargentgloryvine stem, coptis chinensis, rhizoma bletillae, radix gentianae, dragon's blood, cuttlebone, rheum officinale, aloe, catechu, astragalus membranaceus, chloramphenicol and purified water. The capsule is prepared through a powder preparation process, a conventional vaginal medicine filling method is adopted for administration, the capsule is dissolved by virtue of vaginal secretion to release medicine, and the medicine acts on the vagina, the cervix uteri and the endometrium and directly reaches a focus, so that the effects of diminishing inflammation, sterilizing, resisting viruses, diminishing swelling, removing stasis and repairing mucosa are achieved; the traditional Chinese medicine composition can be used for treating colpitis mycotica, infectious microbe vaginitis, cervical erosion, cervicitis, HPV infection and endometritis. The capsule is a proved recipe inherited by several generations, has a good curative effect, takes traditional Chinese medicines as main raw materials, is added with a small amount of western medicines, has the advantages of benefiting and eliminating disadvantages, has no side effect, no preservative and no irritation, has an effective rate of 99% and a cure rate of 98%, and is worthy of popularization.

The invention provides a traditional Chinese medicine composition for treating HPV (human papillomavirus) infection. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 4 to 6 parts of fructus arctii, 3.2 to 4.8 parts of flos lonicerae, 2.4 to 3.6 parts of herba portulacae, 2.4 to 3.6 parts of flos chrysanthemi indici, 1.6 to 2.4 parts of herba menthae, 1.6 to 2.4 parts of flos rosae rugosae, 1.6 to 2.4 parts of liquorice root and 0.8 to 1.2 parts of lucid ganoderma. The invention further provides a preparation method and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition disclosed by the invention is reasonable in raw material medicine compatibility, plays roles of monarch, minister, assistant and guide, treats both symptoms and root causes aiming at the pathogenesis of damp-heat stasis and deficiency in root and excess in superficies, and achieves the purpose of resisting HPV (Human Papilloma Virus).

This invention is directed to immunogenic composition, vaccines and conjugates comprising virus-lie particles (VLP) compositions conjugated to one or more L2 proteins of HPV. The invention further includes methods for the manufacture of immunogenic compositions and vaccines and methods for the treatment and / or prevention of HPV infection.